A5018275689- Diabetes Treatment and Management
- MicroRNA in disease regulation
- Diabetes and associated disorders
- Diabetes Management and Research
- Diet and metabolism studies
- COVID-19 Clinical Research Studies
- Telomeres, Telomerase, and Senescence
- Extracellular vesicles in disease
- Pancreatic function and diabetes
- Cancer-related molecular mechanisms research
- Metabolism, Diabetes, and Cancer
- Adipokines, Inflammation, and Metabolic Diseases
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cardiovascular Function and Risk Factors
- Circular RNAs in diseases
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Liver Disease Diagnosis and Treatment
- Genetics, Aging, and Longevity in Model Organisms
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diet, Metabolism, and Disease
- Long-Term Effects of COVID-19
- Atherosclerosis and Cardiovascular Diseases
- SARS-CoV-2 and COVID-19 Research
- Advanced Glycation End Products research
- Dietary Effects on Health
Istituti di Ricovero e Cura a Carattere Scientifico
2017-2025
MultiMedica
2016-2025
Stellenbosch University
2024
University of Campania "Luigi Vanvitelli"
2024
University of Salerno
2024
ASL Roma
2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2016-2017
Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas
2016-2017
Marche Polytechnic University
2013-2017
Biomedical Research Institute
2016
Microplastics and nanoplastics (MNPs) are emerging as a potential risk factor for cardiovascular disease in preclinical studies. Direct evidence that this extends to humans is lacking.
The role of epigenetics in endothelial cell senescence is a cutting-edge topic ageing research. However, little known the relative contribution to pro-senescence signal propagation provided by microRNAs shuttled extracellular vesicles (EVs) released from senescent cells. Analysis microRNA and DNA methylation profiles non-senescent (control) (SEN) human umbilical vein cells (HUVECs), profiling their cognate small EVs (sEVs) large demonstrated that SEN significantly greater sEV number than...
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors (i) reduce cardiovascular and renal events in patients with without type diabetes (T2D). However, the underlying mechanisms are debated. Low-grade inflammation (LGI) is a key driver of vascular complications, suggested to be attenuated by SGLT-2i animal models. Based on specific working hypothesis, here we investigated net effect LGI T2D possible mechanism. We enrolled treated either stable therapy or other glucose-lowering drugs (GLD) (n =...
Background: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (i) are a class of lipid-lowering drugs suggested to hold plethora beneficial effects independent their LDL cholesterol-lowering properties.However, the mechanism underlying such observations is debated.Methods: Human aortic endothelial cells (TeloHAEC) were pre-treated with 100 µg/mL PCSK9i evolocumab and then exposed 20 ng/mL IL-6, major driver cardiovascular diseases (CVD), in both naïve state after...
No study evaluated the incidence of intra-stent restenosis (ISR)-related events in patients with type 2 diabetes (T2DM) and acute myocardial infarction (AMI) treated or not sodium/glucose cotransporter inhibitors (SGLT2i).We recruited 377 T2DM AMI undergoing percutaneous coronary intervention (PCI). Among them, 177 were SGLT2 before PCI. The primary outcome was major adverse cardiovascular (MACE) defined as cardiac death, re-infarction, heart failure related to ISR. In without ISR, minimal...
Abstract Background Few studies explored the effect of combination glucose sodium-cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on incidence cardiovascular events in patients with type 2 diabetes (T2D) acute myocardial infarction (AMI). Methods We recruited T2D AMI undergoing percutaneous coronary intervention, treated either SGLT-2i or GLP-1RA for at least 3 months before hospitalization. Subjects HbA1c < 7% admission were considered good...
The age-related changes of immune system functions are complex phenomena incompletely understood. acquired shows a functional decline in ability to respond new pathogens during aging, whereas serum levels inflammatory cytokines increased with age. source this systemic chronic inflammation, named inflammaging, was mainly attributed the progressive activation cells over time. However, recent studies have shown that process cellular senescence can be an important additional contributor since...
Diabetic status is characterized by chronic low-grade inflammation and an increased burden of senescent cells. Recently, the senescence-associated secretory phenotype (SASP) has been suggested as a possible source inflammatory factors in obesity-induced type 2 diabetes. However, while senescence known consequence hyperglycaemia, evidences SASP result glycaemic insult are missing. In addition, few data available regarding which cell types main SASP-spreading cells vivo. Adopting four-pronged...
// Fabiola Olivieri 1,2 , Liana Spazzafumo 3 Massimiliano Bonafè 4 Rina Recchioni 2 Francesco Prattichizzo 1 Fiorella Marcheselli Luigina Micolucci Emanuela Mensà Angelica Giuliani Gabriele Santini Mirko Gobbi Raffaella Lazzarini Massimo Boemi 5 Roberto Testa 6 Antonicelli 7 Antonio Domenico Procopio and Anna Rita Bonfigli 8 Department of Clinical Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy Center Pathology Innovative Therapy,...
Aging | doi:10.18632/aging.100693. Fabiola Olivieri, Massimiliano Bonafè, Liana Spazzafumo, Mirko Gobbi, Francesco Prattichizzo, Rina Recchioni, Fiorella Marcheselli, Lucia La Sala, Roberta Galeazzi, Maria Rita Rippo, Gianluca Fulgenzi, Sabrina Angelini, Raffaella Lazzarini, Anna Bonfigli, Francesca Brugè, Luca Tiano, Stefano Genovese, Antonio Ceriello, Massimo Boemi, Claudio Franceschi, Domenico Procopio, Roberto Testa